Drug
LY2605541 clinical trials
Also written LY2605541 and Insulin Peglispro.
- studies test it
- 25
- open now
- 0
- in phase 3
- 10
- first study started
- 2010
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
25 studies that test it; most in 2013 (11)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 5 |
| 2013 | 11 |
| 2014 | 4 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 2
- Phase 3
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses LY2605541 is read from its arms, and is right about nine times in ten.
Testing it · 25
- A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 DiabetesCompletedPhase 3Eli Lilly and CompanyNCT02132637Written as Insulin Peglispro
- A Study of LY2605541 and Glargine in Participants With Type 1 DiabetesCompletedPhase 1Eli Lilly and CompanyNCT01769404Written as LY2605541
- A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin TreatmentCompletedPhase 3Eli Lilly and CompanyNCT01894568Written as Insulin Peglispro
- A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 DiabetesCompletedPhase 1Eli Lilly and CompanyNCT01784211Written as LY2605541
- A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 DiabetesCompletedPhase 1Eli Lilly and CompanyNCT01771250Written as Insulin Peglispro
- A Study of LY2605541 Versus Insulin Glargine on Blood SugarCompletedPhase 1Eli Lilly and CompanyNCT01654380Written as LY2605541
- A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat TissueCompletedPhase 1Eli Lilly and CompanyNCT02109029Written as Insulin Peglispro
- A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 DiabeticsCompletedPhase 1Eli Lilly and CompanyNCT01925989Written as LY2605541
- A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin RequirementsCompletedPhase 1Eli Lilly and CompanyNCT02152384Written as Insulin Peglispro
- A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 DiabeticsCompletedPhase 1Eli Lilly and CompanyNCT02197520Written as Insulin Peglispro
- A Study of LY2605541 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT01877265Written as LY2605541
- A Study of Insulin Peglispro in Healthy Male Japanese ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT01995526Written as Insulin Peglispro
- A Single Dose Study of LY2605541 in Participants With Liver ImpairmentCompletedPhase 1Eli Lilly and CompanyNCT01751399Written as LY2605541
- A Study of LY2605541 in Healthy Participants and in the ElderlyCompletedPhase 1Eli Lilly and CompanyNCT01818245Written as LY2605541
- A Study for Patients With Type 2 DiabetesCompletedPhase 2Eli Lilly and CompanyNCT01027871Written as LY2605541
- A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 DiabetesCompletedPhase 3Eli Lilly and CompanyNCT01790438Written as LY2605541
- A Study of LY2605541 in Participants With Type 1 Diabetes MellitusCompletedPhase 3Eli Lilly and CompanyNCT01792284Written as LY2605541
- A Study of LY2605541 in Participants With Type 2 Diabetes MellitusCompletedPhase 3Eli Lilly and CompanyNCT01582451Written as LY2605541
- A Study for Patients With Type 1 DiabetesCompletedPhase 2Eli Lilly and CompanyNCT01049412Written as LY2605541
- A Study in Participants With Type I Diabetes MellitusCompletedPhase 3Eli Lilly and CompanyNCT01454284Written as LY2605541